(Reuters) - Eli Lilly and Co said on Monday that its top-selling diabetes drug Trulicity significantly reduced the risk of heart attack, stroke and heart-related death in a broad range of people with type 2 diabetes, according to results of a large clinical trial.
Glaxosmithkline’s Tanzeum (Albiglutide) Receives Supplemental Approval In US